University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Katy Tsai, MD

Katy Tsai, MD

Clinical Instructor, Division of Hematology/Oncology, UCSF

Selected Publications

  1. Fitzgerald K, Tsai KK. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019 Mar 01; 38(1):E67-E74.
    View on PubMed
  2. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 Feb 19; 50(2):477-492.e8.
    View on PubMed
  3. Tsai KK, Bollin KB, Patel SP. Obstacles to improving outcomes in the treatment of uveal melanoma. Cancer. 2018 Jul 01; 124(13):2693-2703.
    View on PubMed
  4. Ramstein JJ, Tsai KK, Smith JF. Tyrosine Kinase Inhibitors and Male Reproductive Health. Clin Pharmacol Ther. 2017 Nov; 102(5):754-756.
    View on PubMed
  5. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14).
    View on PubMed
  6. Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 07; 22(7):823-833.
    View on PubMed
  7. Tsai KK, Algazi AP. Are PD-1 antibodies safe for use in metastatic uveal melanoma? Melanoma Manag. 2017 May; 4(2):79-82.
    View on PubMed
  8. Tsai KK, Algazi AP. Melanoma Management. Are PD-1 antibodies safe for use in metastatic uveal melanoma?. 2017; 4(2):79-82.
    View on PubMed
  9. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424.
    View on PubMed
  10. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147.
    View on PubMed
  11. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 02 01; 28(2):368-376.
    View on PubMed
  12. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58.
    View on PubMed
  13. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353.
    View on PubMed
  14. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362.
    View on PubMed
  15. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 09 01; 126(9):3447-52.
    View on PubMed
  16. Tsai KK, Daud AI. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015 Oct 31; 8:123.
    View on PubMed
  17. Tsai KK, Daud AI. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75.
    View on PubMed
  18. Cavanaugh JJ, Jones CD, Embree G, Tsai K, Miller T, Shilliday BB, McGuirt B, Roche R, Pignone M, DeWalt DA, Ratner S. Implementation Science Workshop: primary care-based multidisciplinary readmission prevention program. J Gen Intern Med. 2014 May; 29(5):798-804.
    View on PubMed
  19. Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014; 10(11):3111-6.
    View on PubMed
  20. Kao CH, Hsu CH, Lee JC, Wang HW, Tsai KK. Customized material choice for Asian rhinoplasty: how we do it. Clin Otolaryngol. 2011 Apr; 36(2):165-70.
    View on PubMed

Go to UCSF Profiles, powered by CTSI